Alimta^®

Included as part of a group of medications known as antineoplastics, Alimta^® is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have previously undergone chemotherapy treatment.

Alimta^® is also indicated for use in treating malignant pleural mesothelioma (MPM). In contrast to treatment for non-small cell lung cancer, which can be treated with Alimta^® as a standalone medication, treatment of mesothelioma cancer is administered in combination with cisplatin, a separate anticancer medicine. Treatment for MPM with Alimta^® is indicated for patients whose disease cannot be removed with surgery, as well as for those who are otherwise unable to undergo curative surgery.

At Cancer Treatment Centers of America (CTCA), your team of oncology specialists will determine if Alimta^® is an appropriate treatment option for you. Your team will work with you to develop a comprehensive and individualized plan of cancer care to treat all of you, not just the disease.

Learn more about our whole-patient approach to cancer treatment. Chat now with an Oncology Information Specialist to determine if CTCA is the right treatment facility for you. You can also call us at 1-1-800-615-3055 for more information.

The most common side effect resulting from Alimta^® treatment is an allergic reaction (e.g., difficulty breathing; swelling of the face, lips, tongue or throat; hives). In addition to experiencing these symptoms of an allergic reaction, you should also notify your doctor immediately if you experience any of the following serious side effects:

• Unusual weakness
• Pale skin
• Fever, chills, body aches, flu-like symptoms
• Chest pain, difficulty breathing
• Easy bruising and/or bleeding
• Rapid swelling and/or weight gain
• White patches and/or sores on the lips or in the mouth
• Frequent urination, or stopping of urination altogether

Patients undergoing Alimta^® treatment have more commonly experienced the following, less serious side effects:

• Sore throat
• Fatigue
• Rashes
• Muscle pain and or aches
• Numbness and/or tingling
• Depression
• Nausea, vomiting, indigestion, diarrhea, constipation, loss of appetite

Please note that this is not an all-inclusive list; patients may experience additional side effects not mentioned above.

At Cancer Treatment Centers of America (CTCA), you will be at the center of everything we do. During your cancer treatment at CTCA, you will remain well-informed of the expectations and side effects of Alimta^®, as well as all other treatments you receive. Our unique approach to cancer treatment encourages participation from you and your family. Furthermore, we will ensure that you are comfortable with all decisions made regarding your care.

The primary cancer treated by Alimta^® is malignant pleural mesothelioma (also known simply as MPM). When treating malignant pleural mesothelioma, Alimta^® is administered with another anticancer medication called cisplatin. Alimta^® is used as a treatment option when patients are not candidates for surgery.

Alimta^® is also indicated for treatment following chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Alimta^® can be used as a standalone medication to treat NSCLC.

At Cancer Treatment Centers of America (CTCA), our unique, whole-patient approach ensures that we not only treat your disease, but all of you. Patients at CTCA have the benefit of having their entire care team collaborating and providing care at one location.

Learn more about our cancer treatment facilities by contacting an Oncology Information Specialist today at 1-1-800-615-3055.